Enrolling: Bateman-Horne InTime Drug Intervention Trial

The InTime Trial aims to assess the effects of the investigational drug, CT38, in terms of its safety and effectiveness in treating ME/CFS. There will be 18 people between 18 and 60 years of age enrolled in this study and participation will last up to approximately 4 months.
Who:
Dr. Lucinda Bateman, Located in Salt Lake City, Utah at the Bateman-Horne Institute.

When:

Ongoing


What:

A Clinical Trial for ME/CFS Patients: BHC is conducting a small interventional trial, to test the effectiveness of a new drug that may improve functioning and/or reduce the symptoms in ME/CFS patients. The drug has been shown to be safe in a Phase 1 trial in healthy humans.


Where:

Bateman-Horne Institute, Salt Lake City, Utah


How to Participate:

If you are interested in participating in this trial, please follow the link below and fill out the following form to check for eligibility:
https://redcap01.brisc.utah.edu/ccts/redcap/surveys/?s=MC4EAT4YNE

Facebook
Twitter
WhatsApp
Email

Latest News

Happy Pride Month 2022 with rainbow ribbon in a heart

#MEAction Recognizes & Celebrates Pride Month 2022!

#MEAction recognizes and celebrates Pride Month! As a community that welcomes and encompasses all, this Pride Month, we asked members of our LGBTQIA+ community to share what Pride means to them and what they have learned from this movement that they bring with them to the ME movement. Here are a few responses: Kristina Osobka-Stier

Read More »
Severe ME Artist Project 2022 over swatches of gold paint

Severe ME Artists Project 2022!

#MEAction is once again excited to announce our Severe ME Artists Project 2022 that will feature work from those within the severe ME community and will be in recognition of Severe ME Day on August 8th! This project will be an opportunity for those with severe ME to showcase their art work (whether it be

Read More »

Help keep our work going

We rely on donations from people like you to keep fighting for equality for people with ME.

Donate

Get actions alerts and news direct to your inbox

You can choose what you want to be kept up to date on.

Subscribe
Scroll to Top